Clevudine

Generic Name: Clevudine

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₃FN_₂O_₅

CAS Number: 163252-36-6

Unique Ingredient Identifier: IN51MVP5F1

Indication: 用于慢性乙型肝炎(简称乙肝)的治疗。

Associated Conditions: Viral Hepatitis B

Associated Therapies: -

Clinical Trials

The Proof of Concept Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Mild and Moderate COVID-19

Phase 2

Completed

Conditions: COVID-19

Interventions: Drug: Placebo
Drug: Clevudine

First Posted Date: 2021-05-18

Last Posted Date: 2022-07-22

Lead Sponsor: Bukwang Pharmaceutical

Target Recruit Count: 104

Registration Number: NCT04891302

Locations: 🇰🇷
Korea University Ansan Hospital, Gyeonggi-do, Korea, Republic of
🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of
🇰🇷
Myongji Hospital, Gyeonggi-do, Korea, Republic of

and more 8 locations

The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19

Phase 2

Completed

Conditions: COVID-19

Interventions: Drug: Placebo
Drug: Clevudine

First Posted Date: 2020-04-15

Last Posted Date: 2022-07-22

Lead Sponsor: Bukwang Pharmaceutical

Target Recruit Count: 64

Registration Number: NCT04347915

Locations: 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of

A Study to Compare and Evaluate Intrahepatic cccDNA Reduction After Administrating Clevudine or Entecavir in the Chronic HBV Patients

Phase 4

Terminated

Conditions: Chronic Hepatitis B

Interventions: Drug: Entecavir
Drug: Clevudine

First Posted Date: 2010-12-24

Last Posted Date: 2014-12-18

Lead Sponsor: Bukwang Pharmaceutical

Target Recruit Count: 75

Registration Number: NCT01266005

Locations: 🇰🇷
9 Sites, Seoul, Korea, Republic of

A Study to Evaluate the Efficacy and Safety of Clevudine and Peg-interferon in Sequence Compared With Clevudine Alone in the Patients With HBeAg(+) Chronic Hepatitis B or Clevudine and Peg-interferon Sequential Treatment in Patients With Chronic Hepatitis B Who Have HBeAg(+)

Phase 4

Completed

Conditions: HBeAg(+) Chronic Hepatitis B

Interventions: Drug: Clevudine + Peg-interferon
Drug: Clevudine

First Posted Date: 2010-12-21

Last Posted Date: 2014-12-18

Lead Sponsor: Bukwang Pharmaceutical

Target Recruit Count: 60

Registration Number: NCT01264367

Locations: 🇰🇷
Uijeongbu St.Mary's Hospital, Uijeongbu, Korea, Republic of

A Study to Evaluate the Efficacy and the Change of sAg Levels in Chronic Hepatitis B Patients Receiving Clevudine Treatment Over the Long Period

Phase 4

Terminated

Conditions: Chronic Hepatitis B

First Posted Date: 2010-12-21

Last Posted Date: 2015-07-22

Lead Sponsor: Bukwang Pharmaceutical

Target Recruit Count: 200

Registration Number: NCT01264094

Locations: 🇰🇷
Gangnam Severance Hospital, Seoul, Korea, Republic of

An Study of Efficacy and Safety of Clevudine

Phase 3

Completed

Conditions: Chronic Hepatitis B

Interventions: Drug: Clevudine
Drug: Adefovir

First Posted Date: 2010-09-01

Last Posted Date: 2013-05-14

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 288

Registration Number: NCT01192854

Locations: 🇨🇳
Xiangya hospital, Changsha, Hunan, China

Efficacy of Clevudine Plus Lamivudine for Lamivudine-resistant Chronic Hepatitis B Patients

Phase 4

Terminated

Conditions: Chronic Hepatitis B

Interventions: Drug: adefovir
Drug: lamivudine
Drug: clevudine

First Posted Date: 2008-11-26

Last Posted Date: 2011-06-23

Lead Sponsor: Inje University

Target Recruit Count: 30

Registration Number: NCT00798460

Locations: 🇰🇷
Ilsanpaik hospital, Goyang, Gyunggi, Korea, Republic of

A Pilot Study to Evaluate the Safety and Efficacy of Clevudine or Adefovir Patients With LC-B

Phase 3

Completed

Conditions: Patients With LC-B

Interventions: Drug: Clevudine
Drug: Adefovir dipivoxil

First Posted Date: 2008-05-06

Last Posted Date: 2014-12-18

Lead Sponsor: Bukwang Pharmaceutical

Target Recruit Count: 102

Registration Number: NCT00672867

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

A Double-Blind Randomized Clinical Trial Comparing the Safety and Antiviral Activity of 48-week Clevudine and Adefovir Dipivoxil in HBeAg(-) Chronic Hepatitis B With Compensated Liver Function

Phase 4

Completed

Conditions: HBeAg(-) Chronic Hepatitis B With Compensated Liver Function

Interventions: Drug: Clevudine
Drug: Adefovir dipivoxil

First Posted Date: 2008-03-21

Last Posted Date: 2012-04-25

Lead Sponsor: Bukwang Pharmaceutical

Target Recruit Count: 43

Registration Number: NCT00641082

Locations: 🇰🇷
Seoul National University Bundang Hospital, Bundang, Korea, Republic of
🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Long-term Study With Clevudine

Phase 4

Completed

Conditions: Chronic Hepatitis B

First Posted Date: 2007-11-15

Last Posted Date: 2012-07-26

Lead Sponsor: Bukwang Pharmaceutical

Target Recruit Count: 150

Registration Number: NCT00558818

Locations: 🇰🇷
KoreaUniversity Guro Hospital, Seoul, Korea, Republic of

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy